Carlyle Secured Lending, Inc. - 8.20% Notes due 2028 Stock (NASDAQ: CGBDL)

Latest news for Carlyle Secured Lending, Inc. - 8.20% Notes due 2028 (NASDAQ:CGBDL) Stock

Carlyle Secured Lending, Inc. - 8.20% Notes due 2028

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are trading with mixed results. Several major companies in key sectors reported earnings this week which may be weighing on markets.

News

SMCI

Super Micro Computer Is Said To Tap Evercore To Raise Capital; Super Micro Is Said To Consider Raising Equity And Debt

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 5 years by 14.53% on an annualized basis producing an average annual return of 28.13%. Currently, Blackstone has a market capitalization of $146.32 billion. 
Buying $1000 In BX: If an investor had bought $1000 of BX stock 5 years ago, it would be worth $3,456.08 today based on a price of $188.46 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734123656_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

U.S. Treasury's Yellen Says Banking Supervision Is Critically Important To Reduce Risk Of Bank Failures, Financial Crises; Asked About Trump Considering Moves To Shrink Or Eliminate Bank Regulators, Says Current U.S. System Is Not Broken; Warns Against Interfering With Appropriate Regulation Of Bank Capital, Liquidity, Risk Taking To Ensure Sound Banking System

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 3.93% on an annualized basis producing an average annual return of 15.26%. Currently, Thermo Fisher Scientific has a market capitalization of $200.40 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $4,225.50 today based on a price of $525.00 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734123590_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years

Uranium producer Cameco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) has encountered volatility in recent sessions thanks to opposing fundamental forces tugging on its shares. 
On one hand, the stunning rise of cryptocurrencies implies greater <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/36954312/power-hungry-bitcoin-and-other-cryptos-drained-as-much-power-with-mining-as-whole-of-austr">energy consumption</a> from blockchain mining. Cynically, this framework should be net positive for Cameco stock and the broader nuclear energy industry.
On the other hand, elements such as <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42473889/china-eyes-yuan-devaluation-to-counter-trumps-tariffs-will-it-work">geopolitical tensions</a> and an overall sense of <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios">economic uncertainty</a> have also applied downward pressure on Cameco and other uranium producers recently. 
Therefore, attempting to guess where the company&#8217;s stock may head next appears futile. Instead, it may be better to assume that wherever Cameco goes, it will do so with zest.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13152041/CCJ-stock-12132024-1024x585.jpg" alt="" class="wp-image-692148" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13152041/CCJ-stock-12132024-1024x585.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13152041/CCJ-stock-12132024-300x171.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13152041/CCJ-stock-12132024-768x439.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13152041/CCJ-stock-12132024.jpg 1043w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Currently, the security's price chart shows a broadening formation, also known as a megaphone pattern. Essentially, the price action is charting both a series of higher highs on the upswings and lower lows on the downswing. 
This formation is notoriously difficult to trade as a directional play. However, the underlying rise in volatility offers an attractive opportunity for a long iron condor.
<h2 class="wp-block-heading">Focusing On Volatility Rather Than Direction</h2>
Structurally, the long iron condor is a combination of two vertical spreads: a bear put spread and a bull call spread. In the former strategy's case, the idea is to buy a put and simultaneously sell a put (of the same expiration date) at a lower strike price. Should the security drop below the short put strike price, the trader collects the full reward.
By logical deduction, the opposite applies for the latter strategy. The idea is to buy a call and simultaneously sell a call at a higher strike price. Should the security rise above the short call strike, the trader fully wins. Partial wins are also achieved for these individual vertical spreads if the security breaches the breakeven threshold.
Since the long iron condor combines the bear put and bull call spreads, traders don't care what direction the target security moves to. Rather, the focus is on the magnitude of movement. That's why traders who anticipate a rise in <a href="https://www.benzinga.com/money/what-implied-volatility-options-trading">implied volatility</a> often deploy a long iron condor. To put it simply, kinesis is this option strategy's best friend, while stasis is its enemy.
<h2 class="wp-block-heading">Hunting For The Right Condor</h2>
Since the long iron condor trader profits from rising volatility, all other things being equal, the "narrowest" condors would make the most sense. After all, such structures would easily allow the target security to rise above or fall below the outer strike prices. However, narrow long iron condors generally feature high positional risk (i.e. big money at risk for a small payout) in exchange for the high likelihood of profitability.
On the other side of the table, wider long iron condors tempt traders with typically low positional risk (i.e. less money at risk for a big payout) in exchange for the low likelihood of profitability. Such strategies tend to be speculation traps due to the improbability of making money.
Therefore, trying to find the balance between risk and reward is key with any multi-leg options strategy, especially the condor. That said, one possible idea to consider is the 52P &#x7C; 54P &#x7C;&#x7C; 58C &#x7C; 60C condor for the options chain expiring Dec. 27, 2024. This is how the trade breaks down individually:
<ul>
<li>Sell the $52 put.</li>
<li>Buy the $54 put.</li>
<li>Buy the $58 call.</li>
<li>Sell the $60 call.</li>
</ul>
Cameco stock, at last check, would need to rise roughly 10% to break above the $60 call strike. On the flipside, CCJ could also drop a little less than 5% to break below the $52 put strike. 
Given the security's wild undulations, either outcome is within the realm of possibility (and arguably within the realm of probability).
Further, because CCJ appears to be suffering a bearish bout, the downside target may be more achievable. However, if bullish momentum materializes, traders enjoy decent "coverage" to the upside as well.
Finally, even if traders don't like the 52P &#x7C; 54P &#x7C;&#x7C; 58C &#x7C; 60C condor expiring Dec. 27, the broadening pattern of CCJ stock suggests future volatility-based opportunities. So, keep close tabs on Cameco.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42490520/wall-street-retreats-as-treasuries-suffer-worst-week-in-over-a-year-broadcom-soars-bitcoin-rebounds-whats-driving-markets-friday">Wall Street Retreats As Treasuries Suffer Worst Week In Over A Year, Broadcom Soars, Bitcoin Rebounds: What&#8217;s Driving Markets Friday?</a></li>
</ul>
Image courtesy of Cameco

Commodities

Options

Options Corner: Profit From Cameco Volatility Without Picking A Side

The lawyer assisting <a href="https://www.benzinga.com/topic/robert-f-kennedy-jr">Robert F. Kennedy Jr.</a> in selecting federal health officials for the incoming administration of President-elect Donald Trump has filed a petition urging the government to revoke its approval of the polio vaccine.
The vaccine has safeguarded millions of people for decades against a virus that can cause paralysis or death.
This effort represents just one facet of the broader campaign led by the lawyer, Aaron Siri, who has petitioned for the suspension of 13 other vaccines including COVID as he challenges vaccines across the board and across the country, <a href="https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html">reported </a>the New York Times on Friday.
<h2 class="wp-block-heading">RFK Jr.&#8217;s Anti-Vaccine Campaign Precedes Him</h2>
Long before COVID-19, Kennedy, <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">Trump's pick</a> to lead the Department of Health and Human Services, gained influence through his anti-vaccine nonprofit Children's Health Defense, spreading fear and distrust about vaccines globally. Kennedy has long promoted the debunked link between vaccines and autism.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies">Trump&#8217;s HHS Pick RFK Jr. Has a Long History of Challenging Global Health Policies</a>
One of Siri&#8217;s criticisms of vaccines is that they&#8217;ve not not undergone randomized, double-blind clinical trials; he says they should be removed from the market until such trials are conducted. This approach would involve denying millions of American children access to polio shots, which public health experts consider unethical due to the known risks of polio. 
"You're substituting a theoretical risk for a real risk," <a href="https://www.nytimes.com/2024/12/13/health/aaron-siri-rfk-jr-vaccines.html">said</a> Dr. Paul A. Offit, a vaccine expert at the Children's Hospital of Philadelphia, according to the Times. 
Polio vaccination has been part of the routine childhood immunization schedule in the United States for decades.
Though Kennedy has stated that he does not intend to restrict access to any vaccines, his ongoing collaboration with Siri raises concerns that vaccine policy could face intensified scrutiny. 
<h2 class="wp-block-heading">What Say You, Donald Trump?</h2>
In an <a href="https://time.com/7200212/person-of-the-year-2024-donald-trump/">interview</a> published Thursday by Time magazine, Trump said he's going to direct Kennedy to study the rising rates of autism diagnoses and that he'd consider getting rid of some vaccines for children, falsely suggesting autism may be caused by vaccines.
"We're going to have a big discussion. The autism rate is at a level that nobody ever believed possible. If you look at things that are happening, there's something causing it," Trump said.
<h2 class="wp-block-heading">Bad News For Pharma Companies</h2>
Pharmaceutical companies that produce either standalone polio vaccines or in combination with other immunizations &#8211; GlaxoSmithKline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), Sanofi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and the privately owned Bilthoven Biologicals &#8211; are not likely to view Kennedy and Siri's anti-vaccine push in a positive light.
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) no longer produces the so-called <a href="https://www.cdc.gov/polio/vaccines/index.html#:~:text=Polio%20vaccination%20has%20been%20part,the%20United%20States%20since%202000.">inactivated polio vaccine</a>, which is the only polio vaccine given in the U.S. since 2000, though the company played a key role in the eradication of polio and smallpox.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42488355/bird-flu-spreads-to-cats-possibly-horses-as-officials-signal-no-plans-to-authorize-vaccination">Bird Flu Spreads To Cats, Possibly Horses As Officials Signal No Plans To Authorize Vaccination</a></li>
</ul>
Image via Shutterstock.

Government

Regulations

Health Care

Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children

ATEK

Athena Technology Acquisition Corp. II Receives Commencement Of Delisting Notice From NYSE American; Working Towards Consummating Its Previously Announced Business Combination With Ace Green Recycling; If The Company Securities Are Delisted From NYSE American, The Co Intends To Seek A Listing On The Nasdaq Stock Market

PENN Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) received a Wall Street upgrade Friday on a positive outlook for both its casino and <a href="https://www.benzinga.com/general/sports-betting">sports betting segments.</a>
The PENN Analyst: JPMorgan analyst Joseph Greff upgraded shares of Penn from Neutral to Overweight and raised the price target from $19 to $27.
Read Also: <a href="https://www.benzinga.com/news/24/11/41814090/penn-entertainment-stock-climbs-despite-q3-earnings-miss-whats-going-on">PENN Entertainment Stock Climbs Despite Q3 Earnings Miss: What&#8217;s Going On?</a>
The Analyst Takeaways: Penn has a favorable risk-reward going forward, Greff said in a new investor note.
The analyst said there is a sightline to the "bottoming of its regional land-based casino cashflow generation" and a path to modest growth for its retail projects.
"In addition, we see reasonably set expectations for near-term Interactive (OSB and iGaming) losses for the 4Q24 and 2025 with buy-side expectations for modestly positive EBITDA generation in 2026," Greff said.
Greff said ESPN Bet continues to be one of the biggest drivers for the stock.
"We see a scenario of modestly positive segment EBITDA as not priced in the shares and, importantly, is not that much more than PENN's estimated annual market access fees."
Penn pays Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) for the rights to the ESPN name and brand. Greff said if ESPN Bet is not profitable, the company could shut it down and "milk the $60m-ish of market access fees."
The analyst said company commentary said monthly active users were up 144% year-over-year for ESPN Bet with average handle per user up 64% month-over-month. Enhancements made by Penn to further integrate the ESPN brand into the platform ahead of the NFL season look to have paid off, the analyst added.
The analyst said if ESPN Bet isn't successful, there is still value of the company's land-based casinos and market access fees that sportsbooks pay the company, assigning a value of $26 for this segment.
Penn's $850 million being spent in 2024 and 2025 on four retail growth projects is highlighted by the analyst, which includes replacing a riverboat facility with a land-based casino and hotel, developing a new land-based casino and adding hotels for the Hollywood Columbus and M Resort properties.
"Net-net we see a favorable fundamentally driven risk-reward given improving free cash flow … and shrinking Interactive losses."
PENN Price Action: Penn stock is up 3.60% to $20.73 on Friday versus a 52-week trading range of $13.50 to $27.21. Penn stock is down 20% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/12/42345211/robinhood-ceo-vlad-tenev-says-sports-betting-comments-taken-a-little-bit-out-of-context-but-he-also-wouldnt-rule-it-out">Robinhood CEO Vlad Tenev Says Sports Betting Comments Taken &#8216;A Little Bit Out Of Context,&#8217; But He Also &#8216;Wouldn&#8217;t Rule It Out&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Sports Betting

Upgrades

Price Target

Analyst Ratings

PENN

Penn Stock Analyst Turns Bullish On ESPN Bet Strength, Casino Improvements: 'Favorable Risk-Reward'

BNED

Barnes And Noble Education shares are trading. The company announced released its Q2 financial results.

Cryptocurrency markets are trading higher on Friday as the stock market continues to have a <a href="https://www.benzinga.com/markets/equities/24/10/41421991/ryan-detrick-predicts-bullish-trends-for-s-p-500-historical-data-suggests-significant-gains">bullish outlook for 2025.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$101,697.15</td>
<td>+2.2%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,931.03</td>
<td>+1.6%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$224.50</td>
<td>-1.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.43</td>
<td>&nbsp;+3%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.4063</td>
<td>+0.4%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002846</td>
<td>+1.4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 13.1% and daily active addresses growing by 3.8%. Transactions greater than $100,000 are relatively flat. Exchanges netflows are up by 263.8%.</li>
<li>Coinglass data reports 86,333 traders were liquidated in the past 24 hours for $205.67 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42487721/bitcoin-much-better-than-gold-as-reserve-asset-says-crypto-hedge-fund-founder">Bitcoin &#8216;Much Better Than Gold&#8217; As Reserve Asset, Says Crypto Hedge Fund Founder</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42486061/always-pay-the-tax-man-bitcoin-investor-sentenced-to-two-years-for-tax-evasion-on-crypto-gains">Always Pay The Tax Man: Bitcoin Investor Sentenced To Two Years For Tax Evasion On Crypto Gains</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42486744/the-top-statistics-of-bitcoins-100000-monumental-milestone">The Top Statistics Of Bitcoin&#8217;s $100,000 &#8216;Monumental Milestone&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42480133/do-you-know-warren-buffetts-berkshire-hathaway-has-positions-in-this-lesser-known-crypto-friendly-bank-heres-how-the-stock-has-performed-this-year">Do You Know Warren Buffett&#8217;s Berkshire Hathaway Has Positions In This Lesser-Known Crypto-Friendly Bank? Here&#8217;s How The Stock Has Performed This Year</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42485534/riot-platforms-acquires-5117-bitcoin-for-510million">Riot Platforms Acquires 5,117 Bitcoin For $510Million</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Virtuals Protocol (CRYPTO: VIRTUAL)</td>
<td>&nbsp;$2.45</td>
<td>+24.8%</td>
</tr>
<tr>
<td>JasmyCoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">JASMY</a>)</td>
<td>&nbsp;$0.04802</td>
<td>+14.4%</td>
</tr>
<tr>
<td>Ondo (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ONDO</a>)</td>
<td>&nbsp;$1.96</td>
<td>+11.4%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices reclaiming $101,000, crypto trader Titan of Crypto <a href="https://x.com/Washigorira/status/1867624770889490461">predicts</a> that the 2-month RSI is implying that the crypto king typically peaks 8 to 10 months after breaking its earlier all-time high.
Crypto chart analyst Ali Martinez observed Bitcoin sitting on top of a significant support wall between $94,300 and $100,250, where 2.25 million wallets bought over 2.18 million BTC.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> sits on top of a significant support wall between $94,300 and $100,250, where 2.25 million wallets bought over 2.18 million <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a>. <a href="https://t.co/WdLZXHh8rI">pic.twitter.com/WdLZXHh8rI</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1867598856709714299?ref_src=twsrc%5Etfw">December 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
CryptoCon expressed skepticism about claims of a Bitcoin cycle top arriving soon, predicting that by Q1 2025, most participants in the space will have exited. 
He references data indicating that the typical cycle pattern is on track, with a top expected in late 2025, suggesting strong price action ahead.
The Puell Multiple phases are reportedly aligning with previous cycles, signaling that the market is still in the early stages of a bull run. However, the trader is <a href="https://x.com/CryptoCon_/status/1867647762575015969">curious</a> whether this outlook is based on hope or solid facts.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">When someone says there&#39;s a <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> cycle top coming in the next few months, I can&#39;t help but smile and shake my head&#8230; At this rate, about 90% of our space will have packed their bags after Q1 2025. Meanwhile, data says we&#39;re right on track for normal cycle timing with a top… <a href="https://t.co/dU24IXfwK2">pic.twitter.com/dU24IXfwK2</a>
&mdash; CryptoCon (@CryptoCon_) <a href="https://twitter.com/CryptoCon_/status/1867647762575015969?ref_src=twsrc%5Etfw">December 13, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42490266/bitcoin-to-180000-ethereum-over-6000-solana-to-500-vanecks-2025-crypto-predictions">Bitcoin To $180,000, Ethereum Over $6,000, Solana To $500: VanEck&#8217;s 2025 Crypto Predictions</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$JASMY

$ONDO

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Close The Week Strong: 2025 Could Get Even Better, Say Traders

RGTI

Rigetti shares are trading higher. The stock may be moving in sympathy with Google which recently released its Willow Quantum Computing chip.

FTII

FutureTech II Finds Accounting Errors Affecting 2023 Financials; Restatement In Progress For Q3 2023, Q1 & Q2 2024; Overpayment To Shareholders And Extension Loans Issues; Material Weakness In Controls Admitted; Filing Of Amended Reports With SEC Pending

UPST

Upstart Holdings shares are trading higher after Needham upgraded the stock from Hold to Buy and announced a $100 price target.

NVCR

NovoCure shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $28 to $42.

Shares of SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) are trading higher Friday following a series of favorable announcements highlighting the company's advancements in conversational AI technology. Here&#8217;s <a href="https://www.benzinga.com/quote/SOUN/news">what you need to know.</a>
What To Know: On Thursday, the company's Amelia Conversational AI Platform was recognized as a leader in Frost &amp; Sullivan's 2024 Frost Radar: Enterprise Conversational AI in Healthcare. The report identified SoundHound AI among 14 market leaders out of more than 100 vendors analyzed, citing its innovation and growth in transforming healthcare operations. The platform leverages advanced natural language processing and large language models to improve patient engagement and streamline administrative workflows, including appointment scheduling and IT support.
&#8220;SoundHound&#8217;s Conversational AI Platform stands out for its exceptional performance on both innovation and growth indices is driven by its strong innovation pipeline and an intelligent focus on administrative and operational processes for healthcare organizations,&#8220;said&nbsp;Nitin Manocha, Senior Industry Analyst at Frost &amp; Sullivan.&nbsp;
The Frost &amp; Sullivan report also projected that the enterprise conversational AI market in healthcare would reach $2.34 billion by 2027, growing at a compound annual rate of 17.2%. Analysts noted that SoundHound's acquisition of Amelia positions the company among the largest publicly traded conversational AI firms, with opportunities to expand use cases and deliver value in healthcare.
&#8220;With SoundHound&#8217;s recent acquisition of Amelia, the company now ranks among the largest publicly traded conversational AI companies. By integrating SoundHound&#8217;s advanced voice AI capabilities with Amelia&#8217;s enterprise platform, the company has a tremendous opportunity to unlock more complex use cases and drive real value in the healthcare sector,&#8221; added Manocha.
Additionally, SoundHound announced a partnership with Church's Texas Chicken to implement a voice AI-powered drive-thru ordering solution. The initiative aims to streamline operations, reduce wait times, and enhance staff efficiency.
&#8220;Integrating our technology into Church&#8217;s Texas Chicken restaurants marks a significant milestone in drive-thru innovation,&#8221;&nbsp;said&nbsp;James Hom, Chief Product Officer at SoundHound AI.&nbsp;
SOUN Price Action: SoundHound shares were up 24.8% at $17.05 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-1024x542.png" alt="" class="wp-image-692135" style="width:470px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/13150657/SOUN-2.png 1152w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42490912/teamsters-authorize-strike-at-amazons-new-york-warehouses-get-ready-for-a-fight">Teamsters Authorize Strike At Amazon&#8217;s New York Warehouses: &#8216;Get Ready For A Fight&#8217;</a></li>
</ul>
Image Via Shutterstock.

Movers

SOUN

SoundHound AI Shares Are Surging Friday: What You Need To Know

Invitation Homes's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) short percent of float has fallen 10.47% since its last report. The company recently reported that it has 10.74 million shares sold short, which is 2.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Invitation Homes Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734122721_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Invitation Homes has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Invitation Homes's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Invitation Homes's peer group average for short interest as a percentage of float is 2.36%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

INVH

Looking Into Invitation Homes's Recent Short Interest

Gartner's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) short percent of float has risen 5.65% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 1.87% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Gartner Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734122716_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gartner has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Gartner's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Gartner's peer group average for short interest as a percentage of float is 3.00%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Gartner's Recent Short Interest

Summit Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NYSE">SMMT</a>) short percent of float has risen 5.27% since its last report. The company recently reported that it has 16.84 million shares sold short, which is 14.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Summit Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734122711_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Summit Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Summit Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Summit Therapeutics's peer group average for short interest as a percentage of float is 4.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SMMT

How Is The Market Feeling About Summit Therapeutics?

Value Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALU#NASDAQ">VALU</a>) reported quarterly earnings of $0.60 per share. This is a 62.16 percent increase over earnings of $0.37 per share from the same period last year. The company reported $8.84 million in sales this quarter. This is a 8.00 percent decrease over sales of $9.61 million the same period last year.

Earnings

VALU

Value Line Q2 EPS $0.60 Up From $0.37 YoY, Sales $8.84M Down From $9.61M YoY

Carlyle Secured Lending's 2028 Baby Bonds: An Interesting 7.1-7.8% Yield

2 BDCs Yielding Above 11% That Have Below Average Risk Profile

Carlyle Secured Lending Inc. (CGBD) Q1 2024 Earnings Call Transcript

Carlyle Secured Lending Inc. 2024 Q1 - Results - Earnings Call Presentation

Carlyle Secured Lending Inc. 2024 Q2 - Results - Earnings Call Presentation

Carlyle Secured Lending Inc. (CGBD) Q2 2024 Earnings Call Transcript

BDC Weekly Review: Yield Myopia Ignores The Right Metrics

Carlyle Secured Lending: Baby Bonds Offer 5.9% YTC For 15 Months

Carlyle Secured Lending Inc. (CGBD) Q3 2024 Earnings Call Transcript

Carlyle Secured Lending Inc. 2024 Q3 - Results - Earnings Call Presentation

ARCC

BBDC

BCSF

CGBD

CGBDL

MAIN

MSDL

OBDE

TPVG

Comments

Carlyle Secured Lending, Inc. - 8.20% Notes due 2028

News

Latest news for Carlyle Secured Lending, Inc. - 8.20% Notes due 2028 (NASDAQ:CGBDL) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga